buyWeak
Venrock Healthcare Capital Partners III, L.P. bought $967k of KALV
owner at KalVista Pharmaceuticals, Inc.. 104,489 shares at an average of $9.26, traded Feb 7, 2025, filed Feb 11, 2025.
Conviction score
37Value
$967k
104,489 shares
Holdings after
5,117,285
+2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +25Trade size$967k at market
- 0Relative to holdingsHoldings up 2.1%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-003665, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 7, 2025 | POpen-market purchase Common Stockindirect: By Funds | +73,649 | $9.29 | $684k | 5,086,445 | Feb 11, 2025 |
| Feb 10, 2025 | POpen-market purchase Common Stockindirect: By Funds | +4,137 | $9.14 | $38k | 5,090,582 | Feb 11, 2025 |
| Feb 11, 2025 | POpen-market purchase Common Stockindirect: By Funds | +26,703 | $9.18 | $245k | 5,117,285 | Feb 11, 2025 |
Related signals
Other insiders at KalVista Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 44Moderate | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $905k 33,800 shares | -13% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $60k 2,239 shares | -1% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $53k 1,966 shares | -1% | |
| 21Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $40k 1,489 shares | -2% | |
| 23Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $72k 2,685 shares | -2% | |
| 39Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $293k 10,926 shares | -2% | |
| 23Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $63k 2,358 shares | -1% | |
| 28Weak | KalVista Pharmaceuticals, Inc. | Brian Piekos Chief Financial Officer | $40k 1,489 shares | -6% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $50k 1,861 shares | -3% | |
| 20Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $28k 1,032 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.